Daiichi Sankyo Will Focus On Six Therapeutic Areas
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.
You may also be interested in...
Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
Forest Laboratories and Daiichi Sankyo are building upon an ongoing collaboration for Benicar and Benicar HCT with the signing of a new deal to co-promote the fixed-dose antihypertensive Azor, whose approval is anticipated in September. The companies announced the signing of a letter of intent to enter into a collaboration Aug. 21
Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.
Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.